BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DiaPep277: Phase III data

Data from the modified intent-to-treat (mITT) population (n=338) of the double-blind, international Phase III DIA-AID trial showed that subcutaneous DiaPep277 met the primary endpoint of preserving C-peptide levels from baseline to 24 months vs. placebo. Clal's Andromeda Biotech Ltd. subsidiary said that the decline in C-peptide levels was more pronounced in patients who received placebo compared to DiaPep277, with a significant difference between treatment groups of 0.949 nmol/L/20 minutes (p=0.0374). Andromeda said the difference reflects a relative preservation...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >